- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Exicure Inc (XCUR)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: XCUR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $2
1 Year Target Price $2
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.47% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.47M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 4 | Beta 4.08 | 52 Weeks Range 3.10 - 22.99 | Updated Date 12/14/2025 |
52 Weeks Range 3.10 - 22.99 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.91% | Return on Equity (TTM) -217.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36402068 | Price to Sales(TTM) 74.42 |
Enterprise Value 36402068 | Price to Sales(TTM) 74.42 | ||
Enterprise Value to Revenue 27.17 | Enterprise Value to EBITDA -0.04 | Shares Outstanding 6373869 | Shares Floating 2383954 |
Shares Outstanding 6373869 | Shares Floating 2383954 | ||
Percent Insiders 62.59 | Percent Institutions 6.15 |
About Exicure Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2018-05-22 | CEO & Director Mr. Andy Yoo | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.exicuretx.com |
Full time employees 7 | Website https://www.exicuretx.com | ||
Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

